These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37926768)

  • 1. Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017-2019.
    Poddar A; Raggio M; Concato J
    Ther Innov Regul Sci; 2024 Jan; 58(1):214-221. PubMed ID: 37926768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough Therapy Designation: CDER Analysis of Requests 4 Years Into the Program.
    Conrad R; Taylor K; Raggio M; Harrington A; Stark G; Kish A; Bertha A
    Ther Innov Regul Sci; 2017 Jul; 51(4):509-515. PubMed ID: 30227048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2024 Aug; 25(6):979-997. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the breakthrough-therapy-designated drugs granted in China: A pooled analysis 2020-2022.
    Luo X; Qian F; Yang L; Li Y; Yang Y
    Drug Discov Today; 2022 Dec; 27(12):103370. PubMed ID: 36154876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status.
    Muensterman ET; Luo Y; Parker JM
    Ther Innov Regul Sci; 2020 May; 54(3):658-666. PubMed ID: 33301147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations.
    Hanaizi Z; Kweder S; Thor S; Ribeiro S; Marcal A
    Ther Innov Regul Sci; 2023 Mar; 57(2):321-328. PubMed ID: 36307671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time.
    Miller KL; Stern AD; Kearsley A; Kao J
    Health Aff (Millwood); 2024 Jul; 43(7):1003-1010. PubMed ID: 38950306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician Perceptions of the FDA's Breakthrough Therapy Designation: An Update.
    Paquin RS; Boudewyns V; O'Donoghue AC; Aikin KJ
    Oncologist; 2022 Feb; 27(1):e85-e88. PubMed ID: 35305103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
    Monge AN; Sigelman DW; Temple RJ; Chahal HS
    JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
    Kern KA
    J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
    Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
    BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
    Kajiwara E; Shikano M
    Ther Innov Regul Sci; 2020 Jul; 54(4):814-820. PubMed ID: 32557300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
    Mease C; Miller KL; Fermaglich LJ; Best J; Liu G; Torjusen E
    Orphanet J Rare Dis; 2024 Feb; 19(1):86. PubMed ID: 38403586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Breakthrough Therapy Designation on Development Strategies and Timelines for Nononcology Drugs and Vaccines.
    Poirier AF; Murphy WR
    Clin Pharmacol Ther; 2016 Dec; 100(6):603-605. PubMed ID: 27513678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Impact of US Food and Drug Administration Breakthrough Therapy Designation Timing on Trial Characteristics and Development Speed.
    Pregelj L; Hine DC; Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2021 Oct; 110(4):1018-1024. PubMed ID: 34048058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
    Daizadeh I
    Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies.
    Collins G; Stewart M; McKelvey B; Stires H; Allen J
    Clin Cancer Res; 2023 Jul; 29(13):2371-2374. PubMed ID: 35616593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.